TUSCALMAN SUPPOSITORIES B
TUSCALMAN SUPPOSITORIES B ACTIVE INGREDIENTS Noscapin Hydrocloride – Guaifenisin For the updated summary of product characteristics (SmPC) and package leaflet (PIL) please consult the following link https://www.swissmedicinfo.ch/?Lang=EN We would like to point out that in accordance with current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these […]
TUSCALMAN SUPPOSITORIES A
TUSCALMAN SUPPOSITORIES A ACTIVE INGREDIENTS Noscapin Hydrocloride – Guaifenisin For the updated summary of product characteristics (SmPC) and package leaflet (PIL) please consult the following link https://www.swissmedicinfo.ch/?Lang=EN We would like to point out that in accordance with current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these […]
Tuscalman Syrup
TUSCALMAN Syrup ACTIVE INGREDIENTS Noscapin Hydrocloride – Guaifenisin For the updated summary of product characteristics (SmPC) and package leaflet (PIL) please consult the following link https://www.swissmedicinfo.ch/?Lang=EN We would like to point out that in accordance with current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these details […]
BUCCALIN
BUCCALIN ACTIVE INGREDIENTS Streptococcus Pneumoniae I, II, III – Streptococcus Agalactiae – Staphylococcus Aureus – Haemophilus Influenzae For the updated summary of product characteristics (SmPC) and package leaflet (PIL) please consult the following link https://www.swissmedicinfo.ch/?Lang=EN We would like to point out that in accordance with current legislation, we are unable to provide any information about […]
AKINETON Retard 4mg
AKINETON Retard 4mg ACTIVE INGREDIENTS Biperiden Hydrochloride For the updated summary of product characteristics (SmPC) and package leaflet (PIL) please consult the following link https://www.swissmedicinfo.ch/?Lang=EN We would like to point out that in accordance with current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these details should […]
AKINETON 2mg
AKINETON 2mg ACTIVE INGREDIENTS Biperiden Hydrochloride For the updated summary of product characteristics (SmPC) and package leaflet (PIL) please consult the following link https://www.swissmedicinfo.ch/?Lang=EN We would like to point out that in accordance with current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these details should contact […]
AKINETON Vials
AKINETON Vials ACTIVE INGREDIENTS Biperiden lactate For HCP use only For the updated summary of product characteristics (SmPC) and package leaflet (PIL) please consult the following link https://www.swissmedicinfo.ch/?Lang=EN We would like to point out that in accordance with current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring […]
CPhI Worldwide – 24/26 October 2023
SIT Group takes part in the international exhibition of the pharmaceutical world: CPhI Worldwide from 24 to 26 october 2023 in Barcelona, Spain, stand 2N30.
CPhI Worldwide – 1/3 November 2022
SIT Group takes part in the international exhibition of the pharmaceutical world: CPhI Worldwide from 1 to 2 november 2022 in Frankfurt, Germany, stand 61B41.
CPhI Worldwide – 9/11 November 2021
SIT Group takes part in the international exhibition of the pharmaceutical world: CPhI Worldwide from 9 to 11 november 2021 Milan, Italy, stand 1F41.